INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Anika Therapeutics and its officers or directors [1] Group 1: Company Performance - On July 30, 2025, Anika announced topline results from its pivotal clinical trial of Hyalofast, which showed improvements in treated patients but did not meet pre-specified co-primary endpoints due to a higher dropout rate and missed visits during COVID [3] - Following the announcement, Anika's stock price dropped by $3.06, or 27.42%, closing at $8.10 per share [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Anika for claims related to potential securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered multimillion-dollar damages for class members [4]